Company news

OPKO Health, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.

November 28, 2021

OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results

October 27, 2021

OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021

October 24, 2021

Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency

September 23, 2021

LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories

September 13, 2021

OPKO Health to Participate in Two Upcoming Investment Conferences

August 29, 2021

OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients

August 29, 2021

BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business

August 15, 2021

OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results

July 28, 2021

OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021

July 19, 2021

OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics

July 11, 2021

OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference

July 7, 2021

OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

June 21, 2021

BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry

June 21, 2021

OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics

June 20, 2021

OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland

June 16, 2021

OPKO Health to Participate in the Jefferies Virtual Healthcare Conference

May 26, 2021

OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor

May 23, 2021

OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders

May 6, 2021

OPKO Health Reports 2021 First Quarter Business Highlights and Financial Results

April 27, 2021

Major League Soccer Renews with BioReference Laboratories as COVID-19 Testing Provider for Second Year

April 26, 2021

OPKO Health to Report First Quarter 2021 Financial Results on April 28, 2021

April 21, 2021

BioReference Laboratories Expands Its Major League Sports Relationships with Addition of Major League Baseball

March 31, 2021

BioReference Laboratories Expands COVID-19 School Testing Program

March 25, 2021

EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

February 25, 2021

New York State Partners with BioReference Laboratories to Spearhead the NY Forward COVID-19 Rapid Test Program to Help Reopen the New York Economy

February 21, 2021

OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial Results

February 17, 2021

OPKO Health to Report Fourth Quarter 2020 Financial Results on February 18, 2021

February 2, 2021

New Drug Application Submitted to PMDA in Japan for Somatrogon, to Treat Pediatric Patients with Growth Hormone Deficiency

January 27, 2021

OPKO Health's GeneDx Adds Repeat Expansion Analysis Genetic Tests for Diagnosis of Spinocerebellar Ataxia (SCA), Friedreich Ataxia, and Other Common Forms of Hereditary Ataxia

January 25, 2021

OPKO Health's BioReference Laboratories Team-up with the National Basketball Association and National Hockey League to Provide Players and Staff with COVID-19 Testing

January 25, 2021

OPKO Health's BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access

January 12, 2021

OPKO Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

January 3, 2021

OPKO Health's BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide

January 3, 2021

Buffalo Bills and OPKO Health's BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Program

December 30, 2020

OPKO Health Appoints Dr. Roger Medel to its Board of Directors

December 20, 2020

OPKO Health to Participate in Three Upcoming Investment Conferences

November 10, 2020

OPKO Health Reports 2020 Third Quarter Business Highlights and Financial Results

October 28, 2020

OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test

October 19, 2020

OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020

October 12, 2020

OPKO Health's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools

October 8, 2020

OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients

September 14, 2020

OPKO Health to Participate in Two September Investment Conferences

September 1, 2020

OPKO Health's BioReference Laboratories Announces New York City Schools COVID-19 Testing Program

September 1, 2020

OPKO Health's BioReference Laboratories Launches Best-in-Class Next-Generation Sequencing (NGS) Assay

August 31, 2020

OPKO Health's GeneDx Enters into Agreement with Pediatrix Medical Group to Offer Neonatal Genomic Services

August 11, 2020

OPKO Health's GeneDx Adds GenomeXpress to Its Industry-Leading Clinical Genomics Portfolio

August 5, 2020

OPKO Health to Participate in BTIG Virtual Biotechnology Conference

August 4, 2020

OPKO Health Reports 2020 Second Quarter Business Highlights and Financial Results

July 29, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 31 decks. Every deck is listed under its year.